An Open-label, Dose Escalation, Phase I Study to Evaluate the Tolerability, Safety and Pharmacokinetics of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 26 May 2017
At a glance
- Drugs Afuresertib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; Novartis Pharmaceuticals
- 22 May 2017 Planned End Date changed from 10 Oct 2017 to 27 Dec 2017.
- 15 May 2017 Status changed from recruiting to active, no longer recruiting.
- 08 Aug 2016 Planned number of patients changed from 24 to 18.